- All PLX-treated groups showed improvements in survival rates compared to untreated groups
- PLX-R18 cells did not increase leukocyte levels in non-irradiated NHPs, indicating no requirement to determine levels of radiation exposure prior to administration
- Data will inform a pivotal trial that could support marketing authorization under the FDA’s Animal Rule regulatory pathway
Exopharm to commercialize a new type of nano-drug for regenerative medicine
May 5, 2017, Melbourne, Australia — A private Australian biotechnology company called Exopharm has announced its investment to bring a completely new type of drug called exosomes into local clinical trials.
Exopharm is founded and backed by Dr Ian Dixon, the Melbourne-based technology innovator behind an ASX-listed cell therapy company, the anisina anticancer drug and the Altnia Group incubator. After more than 3 years of secret R&D, Altnia is spinning Exopharm out as a specialist company to translate the promising scientific research around exosomes into routine clinical use worldwide for regenerative medicine. Exopharm will build on its patented purification technology called LEAP to make its proprietary exomeres in large scale and at low cost. [Read more…]
RoosterBio Launches Xeno-Free hMSC Cell Banks to Advance Stem Cell Biomanufacturing
RoosterBio Launches the Regenerative Medicine Industry’s First Xeno-Free hMSC Cell Banks to Advance and Simplify Stem Cell Biomanufacturing
FREDERICK, MARYLAND, May 04, 2017–At a CAGR of 23.2% and estimated revenue of $68B by 2020, the Regenerative Medicine (“RM”) industry continues to call for new tools designed to accelerate this aggressive growth. Based on strong RM market demand, RoosterBio Inc today announces the launch of xeno-free (“XF”) human bone-marrow derived mesenchymal stem/stromal cell (hMSC) products.
Governments on Alert and Stockpiling Antidotes for Nuclear Accidents and Attacks
Many governments, including the U.S. and Japan, are well aware of the dangers to their populations of exposure to high levels of radiation from nuclear accidents or dirty bomb attacks. Whereas Japan’s population was recently exposed at Fukushima following the tsunami of 2011, the U.S. Department of Defense has been stockpiling acute radiation syndrome (ARS) countermeasures as a precaution for many years.
The recent escalation of tensions between North Korea and the U.S. may give the American government cause to up its investment in ARS antidotes. During a military parade on April 15th, North Korea displayed weapons including an intercontinental ballistic missile (ICBM) that could be capable of reaching the U.S. ARS may have just become a larger threat to health than it was just a few weeks ago. [Read more…]
Future of Regenerative Medicine with Kyle Cetrulo of AuxoCell
I had the honor of interviewing Kyle Cetrulo, CEO of AuxoCell Laboratories. In this interview, we explore the upcoming Future of Regenerative Medicine Congress, as well as future directions for regenerative medicine at large. Enjoy. [Read more…]
- « Previous Page
- 1
- …
- 132
- 133
- 134
- 135
- 136
- …
- 201
- Next Page »




